Sagimet doses first patient in U.S. Phase 3 trial of denifanstat for acne

SGMT•2026-10-22

Sagimet Biosciences dosed the first patient in its U.S. Phase 3 AURORA trial of oral denifanstat for moderate to severe acne. The trial plans to enroll about 800 patients, including 450 adolescents, with topline results expected in the second half of 2027.

Sagimet doses first patient in U.S. Phase 3 trial of denifanstat for acne

1. Trial enrollment and timing

Related News

Evonik reportedly considering purchase of US peer such as Ashland

Applied Materials sets fourth-quarter and fiscal 2026 earnings call

E.L.F. Beauty target price raised to $137 from $123 by Canaccord Genuity

Suburban Propane raises quarterly distribution to $0.35 per common unit

P&G reports Q1 adjusted core EPS of $2.00 vs. $1.88 estimate